Company Filing History:
Years Active: 1989-2006
Title: The Innovative Contributions of Pamela A. Havre
Introduction
Pamela A. Havre is a distinguished inventor based in New Haven, CT (US). She has made significant contributions to the field of molecular biology, particularly in the development of innovative oligonucleotides and peptides. With a total of 2 patents, her work has the potential to impact therapeutic strategies in various medical applications.
Latest Patents
One of her latest patents is titled "Chemically modified oligonucleotide for site-directed mutagenesis." This invention involves a mutagenic, triplex-forming oligonucleotide that is chemically modified to incorporate a mutagen. It forms a triple-stranded nucleic acid molecule with a specific DNA segment of a target DNA molecule. Upon formation of the triplex, the mutagen is brought into proximity with the target molecule, causing a mutation at a specific site. This mutation can activate, inactivate, or alter the activity and function of the target molecule.
Another notable patent is the "Translation inhibiting peptide." This peptide causes a suppression in protein synthesis by halting the translation of mRNA into protein. The peptide has a Stokes radius of less than 16 Angstroms, a molecular weight of 17 kD, indicating that it is a monomer, and an isoelectric point of 7.25. The therapeutic advantages of this peptide may include halting the proliferation of abnormal or excess protein.
Career Highlights
Pamela A. Havre is affiliated with Yale University, where she continues her research and development in the field of molecular biology. Her innovative work has garnered attention and respect within the scientific community.
Collaborations
Throughout her career, Pamela has collaborated with notable colleagues, including Peter M. Glazer and Graeme L. Hammond. These collaborations have further enriched her research and contributed to her success as an inventor.
Conclusion
Pamela A. Havre's contributions to the field of molecular biology through her innovative patents demonstrate her commitment to advancing scientific knowledge and therapeutic applications. Her work continues to inspire future research and innovation in the field.